TW200726764A - N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions - Google Patents

N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions

Info

Publication number: TW200726764A
Authority: TW; Taiwan
Prior art keywords: treatment; thrombotic conditions; linked heterocyclic; receptor useful; receptor
Prior art date: 2005-06-27

Application number

TW095122981A

Other languages

English (en)

Inventor

Jennifer X Qiao

Tammy C Wang

James C Sutton

Timur Gungor

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-06-27

Filing date

2006-06-26

Publication date

2007-07-16

2006-06-26 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2007-07-16 Publication of TW200726764A publication Critical patent/TW200726764A/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Diabetes (AREA)
Cardiology (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

TW095122981A 2005-06-27 2006-06-26 N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions TW200726764A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US69459605P	2005-06-27	2005-06-27
US79706406P	2006-05-02	2006-05-02

Publications (1)

Publication Number	Publication Date
TW200726764A true TW200726764A (en)	2007-07-16

Family

ID=37087734

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW095122981A TW200726764A (en)	2005-06-27	2006-06-26	N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions

Country Status (13)

Country	Link
US (2)	US7728008B2 (zh)
EP (1)	EP1896466B1 (zh)
JP (1)	JP2008543972A (zh)
KR (1)	KR20080027890A (zh)
AR (1)	AR056867A1 (zh)
AT (1)	ATE505468T1 (zh)
AU (1)	AU2006261828A1 (zh)
DE (1)	DE602006021306D1 (zh)
MX (1)	MX2007016501A (zh)
NO (1)	NO20076424L (zh)
PE (1)	PE20070016A1 (zh)
TW (1)	TW200726764A (zh)
WO (1)	WO2007002637A1 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7550499B2 (en)	2004-05-12	2009-06-23	Bristol-Myers Squibb Company	Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
DE602006020327D1 (de) *	2005-01-19	2011-04-07	Bristol Myers Squibb Co	2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-aminder-hemmer zur behandlung thromboembolischer erkrankungen
US7700620B2 (en) *	2005-06-27	2010-04-20	Bristol-Myers Squibb Company	C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7714002B2 (en) *	2005-06-27	2010-05-11	Bristol-Myers Squibb Company	Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2007002584A1 (en)	2005-06-27	2007-01-04	Bristol-Myers Squibb Company	Linear urea mimics antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
US7960569B2 (en) *	2006-10-17	2011-06-14	Bristol-Myers Squibb Company	Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
EP2571357B1 (en)	2010-05-21	2016-07-06	Infinity Pharmaceuticals, Inc.	Chemical compounds, compositions and methods for kinase modulation
KR20140063605A (ko)	2011-07-19	2014-05-27	인피니티 파마슈티칼스, 인코포레이티드	헤테로사이클릭 화합물 및 그의 용도
AR091790A1 (es)	2011-08-29	2015-03-04	Infinity Pharmaceuticals Inc	Derivados de isoquinolin-1-ona y sus usos
EP2880034B1 (en)	2012-08-01	2016-06-22	Bristol-Myers Squibb Company	Amino-heteroaryl 7-hydroxy-spiropiperidine indolinyl antagonists of p2y1 receptor
WO2014022343A1 (en)	2012-08-01	2014-02-06	Bristol-Myers Squibb Company	7-hydroxy-indolinyl antagonists of p2y1 receptor
EP2892898B1 (en) *	2012-08-01	2016-05-25	Bristol-Myers Squibb Company	7-hydroxy-spiropipiperidine indolinyl antagonists of p2y1 receptor
KR20150087400A (ko)	2012-11-20	2015-07-29	버텍스 파마슈티칼스 인코포레이티드	인돌아민 2,3-디옥시게나제의 억제제로서 유용한 화합물
US9481667B2 (en)	2013-03-15	2016-11-01	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CA3113234A1 (en)	2018-09-18	2020-03-26	Nikang Therapeutics, Inc.	Tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors
CN110305141B (zh) *	2019-07-18	2022-01-11	深圳市三启药物开发有限公司	一种螺(3,3’-异丙基吡咯烷氧化吲哚)类肝x受体调节剂及其制备方法和应用

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3118888A (en)		1964-01-21		Acylated s-triazines and process for their preparation
NL280954A (zh)	1961-07-14
US4179563A (en)	1978-05-19	1979-12-18	Warner-Lambert Company	3-Aryloxy-substituted-aminopyridines and methods for their production
US4186199A (en) *	1978-11-02	1980-01-29	American Hoechst Corporation	Indolo-,1,2-dihydroindolo-, and 1,2,6,7-tetrahydroindolo [1,7-ab][1,5] benzodiazepines
EP0028489B1 (en)	1979-11-05	1983-10-05	Beecham Group Plc	Enzyme derivatives, and their preparation
JPS56166180A (en)	1980-05-28	1981-12-21	Chugai Pharmaceut Co Ltd	Dibenzoxazepine derivative and its preparation
JPS56167649A (en)	1980-05-30	1981-12-23	Chugai Pharmaceut Co Ltd	Diphenyl ether derivative
US4761411A (en) *	1983-05-18	1988-08-02	Hoechst-Roussel Pharmaceuticals Inc.	Dihydrobenzopyrrolobenzodiazepines useful for treating pyschoses
US4663453A (en)	1983-05-18	1987-05-05	Hoechst-Roussel Pharmaceuticals Inc.	Benzo[b]pyrrolo[3,2,1-jk][1,4]benzodiazepines having dopamine receptor activity
JPS62280847A (ja)	1986-05-30	1987-12-05	Konica Corp	新規なマゼンタカプラ−を含有するハロゲン化銀写真感光材料
US4840947A (en)	1986-10-14	1989-06-20	Hoechst-Roussel Pharmaceuticals, Inc.	Antiinflammatory and analgesic piperidin-4-yl-tetracyclic benzodiazepines and use thereas
JP2577222B2 (ja)	1987-04-10	1997-01-29	興和株式会社	新規な置換アニリド誘導体
JPH0339740A (ja)	1989-07-06	1991-02-20	Konica Corp	転写型熱現像カラー感光材料
JP2951434B2 (ja)	1991-04-18	1999-09-20	三菱製紙株式会社	電子写真感光体
NZ264063A (en)	1993-08-13	1995-11-27	Nihon Nohyaku Co Ltd	N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
JP3395285B2 (ja)	1993-10-06	2003-04-07	日本製紙株式会社	感熱記録体
US5547966A (en)	1993-10-07	1996-08-20	Bristol-Myers Squibb Company	Aryl urea and related compounds
US5612359A (en)	1994-08-26	1997-03-18	Bristol-Myers Squibb Company	Substituted biphenyl isoxazole sulfonamides
DE4443641A1 (de)	1994-12-08	1996-06-13	Bayer Ag	Substituierte Carbonsäureamide
EP0809492A4 (en)	1995-02-17	2007-01-24	Smithkline Beecham Corp	IL-8 RECEPTOR ANTAGONISTS
PL322843A1 (en)	1995-03-20	1998-02-16	Lilly Co Eli	5-substituted 3-91,2,3,6-tetrahydropyridin-4-yl)- and 3-9piperydin-4-4-yl0-1h-indoles nevel 5-htif natagonists
AU7340096A (en)	1995-11-07	1997-05-29	Kirin Beer Kabushiki Kaisha	Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
ES2221049T3 (es)	1996-03-25	2004-12-16	Eli Lilly And Company	Compuestos de tetrahidrobetacarbolino.
JP2001504097A (ja) *	1996-10-30	2001-03-27	ザ・ユニヴァーシティ・オブ・ノース・キャロライナ・アト・チャペル・ヒル	Ｐ２ｙレセプターアンタゴニスト
US6020357A (en)	1996-12-23	2000-02-01	Dupont Pharmaceuticals Company	Nitrogen containing heteroaromatics as factor Xa inhibitors
US6187797B1 (en)	1996-12-23	2001-02-13	Dupont Pharmaceuticals Company	Phenyl-isoxazoles as factor XA Inhibitors
TW536540B (en)	1997-01-30	2003-06-11	Bristol Myers Squibb Co	Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US5858289A (en)	1997-02-24	1999-01-12	Global Consulting, Inc.	Process for preparing compressed shape of ceramic fiber
ZA985247B (en)	1997-06-19	1999-12-17	Du Pont Merck Pharma	Guanidine mimics as factor Xa inhibitors.
ID24289A (id)	1997-11-10	2000-07-13	Bristol Myers Squibb Co	Benzotiazol inhibitor-inhibitor protein terosin kinase
JP2002508366A (ja)	1997-12-12	2002-03-19	スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー	キノリンピペラジンおよびキノリンピペリジン誘導体、それらの製造方法、ならびに複合的５−ｈｔ１ａ、５−ｈｔ１ｂおよび５−ｈｔ１ｄ受容体アンタゴニストとしてのそれらの用途
US7517880B2 (en)	1997-12-22	2009-04-14	Bayer Pharmaceuticals Corporation	Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
CA2315715C (en)	1997-12-22	2010-06-22	Bayer Corporation	Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US6329395B1 (en)	1998-06-08	2001-12-11	Schering Corporation	Neuropeptide Y5 receptor antagonists
ES2318899T3 (es)	1998-07-06	2009-05-01	Bristol-Myers Squibb Company	Bifenil sulfonamidas como antagonistas duales de los receptores de angiotensina y endotelina.
HUP0104026A3 (en)	1998-10-06	2002-06-28	Dainippon Pharmaceutical Co	2,3-disubstituted pyridine derivatives, process for the preparation thereof, drug compositions containing the same and intermediates for the preparation
US7160887B1 (en)	1998-10-20	2007-01-09	Takeda Pharmaceutical Company Limited	Aromatic amine derivatives, their production and use
GB9823873D0 (en)	1998-10-30	1998-12-30	Pharmacia & Upjohn Spa	2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
ID30176A (id)	1999-03-12	2001-11-08	Boehringer Ingelheim Pharma	Senyawa-senyawa yang bermanfaat sebagai zat anti-inflamasi
US6548529B1 (en)	1999-04-05	2003-04-15	Bristol-Myers Squibb Company	Heterocyclic containing biphenyl aP2 inhibitors and method
ID30460A (id)	1999-04-15	2001-12-06	Bristol Myers Squibb Co	Inhibitor-inhibitor protein siklik tirosin kinase
WO2000076970A2 (en)	1999-06-14	2000-12-21	Eli Lilly And Company	Serine protease inhibitors
CO5200760A1 (es)	1999-06-16	2002-09-27	Smithkline Beecham Corp	Antagonistas del receptor de la il-8 ceptor il-8
JP2001089412A (ja)	1999-09-22	2001-04-03	Otsuka Pharmaceut Co Ltd	ベンゼン誘導体またはその医薬的に許容される塩
WO2001023358A1 (en)	1999-09-27	2001-04-05	Sagami Chemical Research Center	Pyrazole derivatives, intermediates for the preparation thereof, processes for the preparation of both and herbicides containing the derivatives as the active ingredient
MY125533A (en)	1999-12-06	2006-08-30	Bristol Myers Squibb Co	Heterocyclic dihydropyrimidine compounds
DE19962924A1 (de)	1999-12-24	2001-07-05	Bayer Ag	Substituierte Oxazolidinone und ihre Verwendung
AU2001230913B2 (en)	2000-01-14	2005-06-30	The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Methanocarba cycloalkyl nucleoside analogues
US20030065176A1 (en)	2000-01-29	2003-04-03	Myung-Gyun Kang	Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof
US6906063B2 (en) *	2000-02-04	2005-06-14	Portola Pharmaceuticals, Inc.	Platelet ADP receptor inhibitors
SK12712002A3 (sk)	2000-02-07	2003-02-04	Abbott Gmbh & Co. Kg	Deriváty 2-benzotiazolylmočoviny a ich použitie ako inhibítorov proteínkináz
WO2001072751A1 (en)	2000-03-29	2001-10-04	Knoll Gesellschaft Mit Beschraenkter Haftung	Pyrrolopyrimidines as tyrosine kinase inhibitors
WO2001074793A2 (en)	2000-04-03	2001-10-11	3-Dimensional Pharmaceuticals, Inc.	Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
AR035216A1 (es)	2000-12-01	2004-05-05	Astrazeneca Ab	Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US6693196B2 (en)	2001-01-31	2004-02-17	The Procter & Gamble Company	Couplers for use in oxidative hair dyeing
WO2002064211A1 (en)	2001-02-09	2002-08-22	Merck & Co., Inc.	Thrombin inhibitors
CA2445357A1 (en)	2001-04-27	2002-11-07	Vertex Pharmaceuticals Incorporated	Pyrazole derived kinase inhibitors
CA2453223A1 (en)	2001-05-08	2002-11-14	Schering Aktiengesellschaft	Selective anthranilamide pyridinamides as vegfr-2 and vegfr-3 inhibitors
WO2003007955A2 (en)	2001-07-20	2003-01-30	Cancer Research Technology Limited	Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
JP2005501873A (ja)	2001-07-31	2005-01-20	バイエル・ヘルスケア・アクチェンゲゼルシャフト	アミン誘導体
EA006769B1 (ru)	2001-08-06	2006-04-28	Фармация Италия С.П.А.	Производные аминоизоксазола в качестве ингибиторов киназы
GEP20074098B (en)	2001-09-21	2007-05-10	Bristol Myers Squibb Co	Lactam-containing compounds and derivatives thereof as factor xa inhibitors
EP1451156A4 (en)	2001-11-27	2005-05-25	Merck & Co Inc	4-AMINOCHINOLINVERBINDUNGEN
JP2003192587A (ja)	2001-12-26	2003-07-09	Bayer Ag	尿素誘導体
WO2003055848A2 (en)	2001-12-26	2003-07-10	Bayer Healthcare Ag	Urea derivatives as vr1- antagonists
SI1478358T1 (sl)	2002-02-11	2013-09-30	Bayer Healthcare Llc	Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
US20030216396A1 (en)	2002-02-11	2003-11-20	Bayer Corporation	Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
US20040023961A1 (en)	2002-02-11	2004-02-05	Bayer Corporation	Aryl ureas with raf kinase and angiogenisis inhibiting activity
DE10213228A1 (de)	2002-03-25	2003-10-16	Bayer Ag	Cyclopenten-Derivate
CN1665808A (zh)	2002-05-06	2005-09-07	沃泰克斯药物股份有限公司	噻二唑或噁二唑及其作为jak蛋白激酶抑制剂的用途
EP1531815B1 (en)	2002-06-27	2014-09-24	Novo Nordisk A/S	Glucokinase activators
CN1671378A (zh)	2002-08-01	2005-09-21	神经研究公司	用于治疗对抗血管生成疗法有应答的疾病的化合物
DE60328202D1 (de)	2002-09-05	2009-08-13	Neurosearch As	Diarylharnstoffderivate und deren verwendung als chloridkanalblocker
EP1402888A1 (en)	2002-09-18	2004-03-31	Jerini AG	The use of substituted carbocyclic compounds as rotamases inhibitors
US20040209930A1 (en)	2002-10-02	2004-10-21	Carboni Joan M.	Synergistic methods and compositions for treating cancer
ES2327834T3 (es)	2002-11-21	2009-11-04	Neurosearch A/S	Derivados de diarilureido y su uso medico.
US7056889B2 (en)	2002-12-16	2006-06-06	Kimberly-Clark, Worldwide, Inc.	Compounds that bind P2Y2 or P2Y1 receptors
TWM252710U (en)	2003-07-18	2004-12-11	Huei-Chiun Shiu	Annealing equipment
WO2005012221A1 (ja)	2003-08-04	2005-02-10	Ono Pharmaceutical Co., Ltd.	ジフェニルエーテル化合物、その製造方法および用途
JP2007502283A (ja)	2003-08-13	2007-02-08	アムジェンインコーポレイテッド	メラニン凝集ホルモン受容体アンタゴニスト
ES2711313T3 (es) *	2003-12-26	2019-05-03	Masatoshi Hagiwara	Método de regulación de la fosforilación de la proteína SR y agentes antivirales que comprenden el regulador de la actividad de la proteína SR como ingrediente activo
US7470712B2 (en)	2004-01-21	2008-12-30	Bristol-Myers Squibb Company	Amino-benzazoles as P2Y1 receptor inhibitors
WO2005113511A1 (en)	2004-05-12	2005-12-01	Bristol-Myers Squibb Company	Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
US7550499B2 (en)	2004-05-12	2009-06-23	Bristol-Myers Squibb Company	Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
DE602006020327D1 (de)	2005-01-19	2011-04-07	Bristol Myers Squibb Co	2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-aminder-hemmer zur behandlung thromboembolischer erkrankungen
JP4377942B2 (ja)	2005-02-25	2009-12-02	セレネックス，インコーポレイテッド	テトラヒドロインドロン及びテトラヒドロインダゾロン誘導体
US7714002B2 (en)	2005-06-27	2010-05-11	Bristol-Myers Squibb Company	Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7700620B2 (en)	2005-06-27	2010-04-20	Bristol-Myers Squibb Company	C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2007002584A1 (en)	2005-06-27	2007-01-04	Bristol-Myers Squibb Company	Linear urea mimics antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
US7960569B2 (en)	2006-10-17	2011-06-14	Bristol-Myers Squibb Company	Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions

2006
- 2006-06-26 DE DE602006021306T patent/DE602006021306D1/de active Active
- 2006-06-26 KR KR1020087002124A patent/KR20080027890A/ko not_active Withdrawn
- 2006-06-26 MX MX2007016501A patent/MX2007016501A/es not_active Application Discontinuation
- 2006-06-26 TW TW095122981A patent/TW200726764A/zh unknown
- 2006-06-26 AU AU2006261828A patent/AU2006261828A1/en not_active Abandoned
- 2006-06-26 AR ARP060102745A patent/AR056867A1/es unknown
- 2006-06-26 JP JP2008519471A patent/JP2008543972A/ja active Pending
- 2006-06-26 WO PCT/US2006/024914 patent/WO2007002637A1/en not_active Ceased
- 2006-06-26 EP EP06774067A patent/EP1896466B1/en active Active
- 2006-06-26 US US11/474,888 patent/US7728008B2/en active Active
- 2006-06-26 AT AT06774067T patent/ATE505468T1/de not_active IP Right Cessation
- 2006-06-27 PE PE2006000739A patent/PE20070016A1/es not_active Application Discontinuation
2007
- 2007-12-14 NO NO20076424A patent/NO20076424L/no not_active Application Discontinuation
2010
- 2010-04-16 US US12/761,447 patent/US8329718B2/en active Active

Also Published As

Publication number	Publication date
KR20080027890A (ko)	2008-03-28
PE20070016A1 (es)	2007-02-11
AU2006261828A1 (en)	2007-01-04
US7728008B2 (en)	2010-06-01
WO2007002637B1 (en)	2007-03-01
DE602006021306D1 (zh)	2011-05-26
AR056867A1 (es)	2007-10-31
US8329718B2 (en)	2012-12-11
EP1896466B1 (en)	2011-04-13
US20100197716A1 (en)	2010-08-05
US20060293281A1 (en)	2006-12-28
NO20076424L (no)	2008-03-18
ATE505468T1 (de)	2011-04-15
WO2007002637A1 (en)	2007-01-04
JP2008543972A (ja)	2008-12-04
EP1896466A1 (en)	2008-03-12
MX2007016501A (es)	2008-03-06

Publication	Publication Date	Title
NO20076424L (no)	2008-03-18	N-koblete heterocykliske antagonister av P2Y1 reseptoren nyttige for behandling av tromboseforstyrrelser
WO2007002635A3 (en)	2007-03-29	C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
WO2008048981A3 (en)	2008-09-18	Indole antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
EE200300403A (et)	2003-12-15	N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
MY132566A (en)	2007-10-31	Benzimidazolone histamine h3 antagonists
NO20092286L (no)	2009-08-13	Nitrogenhaldige heterosykliske forbindelser og anvendelse derav
MX2010006230A (es)	2010-06-23	Derivados de arilamida substituidos con triazol y su uso como antagonistas de receptor purinergico p2x3 y/o p2x2/3.
TW200738729A (en)	2007-10-16	Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
WO2005113537A3 (en)	2005-12-22	Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
MXPA05013474A (es)	2006-03-09	Derivados de quinolilamida como antagonistas de ccr-5.
PL1620425T3 (pl)	2009-06-30	Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu
UA101602C2 (ru)	2013-04-25	Производные бензамидов как антагонисты брадикининовых рецепторов
MX2009004314A (es)	2009-05-05	Diaril, dipiridinil y arilpiridinilderivados y usos de los mismos.
NO20080033L (no)	2008-01-03	Kinolinderivater som NK3-antagonister
NO20061137L (no)	2006-03-09	Cyklopropylderivater som NK3-reseptorantagonister
DE602006020871D1 (de)	2011-05-05	Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
MXPA05013151A (es)	2006-03-17	3-fluoro-piperidinas como antagonistas de n-metil-d-aspartato/nr2b.
WO2005075450A3 (en)	2006-03-30	Spiro-benzodioxoles and their use as cb1 antagonists
MX2007006387A (es)	2007-06-20	Derivados de piridina 3-substituidos como antagonistas h3.
DE602006018713D1 (de)	2011-01-20	Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
IS8377A (is)	2006-03-27	Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
ZA200704913B (en)	2008-09-25	3-[2-(3-acylamino-2-oxo-2H-pyridin-1-YL)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors
TW200606153A (en)	2006-02-16	Process for producing pyridine derivatives of Nk-1 receptor antagonist
MX2009000762A (es)	2009-01-28	4-arilalcoximetil-4-fenil piperidinas y su uso como antagonistas del receptor de neuroquinina para el tratamiento de trastornos del sistema nervioso central.
DE602005007765D1 (de)	2008-08-07	Neue indol- oder benzimidazol-derivate